scholarly journals Comparison of long‐term use of prolonged‐release ropinirole and immediate‐release dopamine agonists in an observational study in patients with Parkinson's disease

2020 ◽  
Vol 29 (5) ◽  
pp. 591-598 ◽  
Author(s):  
Usha Gungabissoon ◽  
Oksana Kirichek ◽  
Céline El Baou ◽  
Nicholas Galwey
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Observational Study ◽  
Dopamine Agonists ◽  
Immediate Release ◽  
Prolonged Release

scholarly journals Treatment of Parkinson’s disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches

1984 ◽  
Vol 11 (S1) ◽  
pp. 210-220 ◽  
Author(s):  
Anthony E. Lang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Agonists ◽  
New Approaches ◽  
Wide Range ◽  
The Many ◽  
Treatment Alternatives

ABSTRACTParkinson’s disease is associated with a variety of neurotransmitter disturbances which may be further altered by its treatment with dopamine agonists. Based on this information a wide range of pharmacological approaches have been used in search of newer treatment alternatives and in hopes of reducing complications of long-term levodopa use. This paper reviews the various therapies which have had some success in the management of Parkinson’s disease, other than levodopa and dopamine agonists. Special emphasis is placed on the many unresolved questions and controversies that exist in this area of neuropharmacology.

New Pharmacotherapy for Parkinson's Disease

1997 ◽  
Vol 31 (10) ◽  
pp. 1205-1217 ◽  
Author(s):  
Mildred D Gottwald ◽  
Jacquelyn L Bainbridge ◽  
Glenna A Dowling ◽  
Michael J Aminoff ◽  
Brian K Alldredge
Keyword(s):  
Parkinson’S Disease ◽  
Clinical Trial ◽  
Parkinson's Disease ◽  
Clinical Studies ◽  
Dopamine Agonists ◽  
Motor Fluctuations ◽  
Phase Iii ◽  
Pharmacokinetic Data ◽  
Comt Inhibitors

OBJECTIVE: To summarize the development, pharmacology, pharmacokinetics, efficacy, and safety of five investigational antiparkinsonian drugs that are in or have recently completed Phase III trials: three dopamine agonists, pramipexole, ropinirole, and cabergoline; and two catechol- O-methyltransferase (COMT) inhibitors, entacapone and tolcapone. The pathophysiology and the role of dopamine in Parkinson's disease are also reviewed. DATA SOURCES: A MEDLINE search of relevant English-language literature, clinical studies, abstracts, and review articles pertaining to Parkinson's disease was conducted. Manual searches of 1996/1997 meeting abstracts published by the American Academy of Neurology and the Movement Disorders Society were also performed. Manufacturers provided unpublished Phase III trial efficacy and pharmacokinetic data. STUDY SELECTION AND DATA EXTRACTION: Clinical trial investigations selected for inclusion were limited to human subjects. Interim analyses after 6 months for long-term clinical trial studies in progress were included. Pharmacokinetic data from animals were cited if human data were unavailable. Statistical analyses for all studies were evaluated. DATA SYNTHESIS: By selectively targeting D2 receptors, the newer dopamine agonists (i.e., cabergoline, pramipexole, ropinirole) may delay the introduction of levodopa and thus the occurrence of levodopa-induced dyskinesias. In addition, they are efficacious as adjunctive therapies in patients with advanced Parkinson's disease. Unlike the currently available dopamine agonists, pramipexole and ropinirole are non-ergot derivatives and do not cause skin inflammation, paresthesias, pulmonary infiltrates, or pleural effusion. The COMT inhibitors, tolcapone and entacapone, improve the pharmacokinetics of levodopa by preventing its peripheral catabolism and increasing the concentration of brain dopamine; thus, these agents may reduce the incidence of “wearing-off ' effects associated with the short half-life of levodopa and the progression of Parkinson's disease. CONCLUSIONS: Interim 6-month analyses of pramipexole, ropinirole, and cabergoline for symptomatic treatment of early Parkinson's disease have shown these drugs to be efficacious and relatively well-tolerated when used as monotherapy. Their role in delaying the development of motor fluctuations and delaying the addition of levodopa is the subject of long-term clinical studies. In advanced stages of Parkinson's disease, these medications were also efficacious; however, the main adverse effects included dyskinesias, somnolence, and hallucinations. The COMT inhibitors, entacapone and tolcapone, have also demonstrated efficacy in improving on-time in patients with stable disease. Tolcapone has also demonstrated efficacy in patients with motor fluctuations. Both drugs are relatively well-tolerated, with the exception of dyskinesias that require reduction of the levodopa dosage and occasional diarrhea.

Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease

2014 ◽  
Vol 126 (1) ◽  
pp. 30-38 ◽  
Author(s):  
Clare W. Makumi ◽  
Afsaneh Asgharian ◽  
Jeffrey Ellis ◽  
Soraya Shaikh ◽  
Teri Jimenez ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Prolonged Release ◽  
Open Label ◽  
Safety Study ◽  
Once Daily ◽  
Advanced Parkinson’S Disease

Long-term, Open-label Study of Once-daily Ropinirole Prolonged Release in Early Parkinson's Disease

2011 ◽  
Vol 121 (5) ◽  
pp. 246-253 ◽  
Author(s):  
Robert A. Hauser ◽  
Heinz Reichmann ◽  
Mark Lew ◽  
Afsaneh Asgharian ◽  
Clare Makumi ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Prolonged Release ◽  
Open Label ◽  
Once Daily ◽  
Open Label Study ◽  
Label Study ◽  
Early Parkinson’S Disease
Sign in / Sign up

Export Citation Format

Share Document